Company intelligence / Profile preview
Tauriga Sciences
New York, New York, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
The company has developed a proprietary pharmaceutical-grade chewing gum (Tauri-Gum) containing CBD, targeting nausea relief for patients undergoing chemotherapy and has filed a provisional US patent; clinical results are not yet available[1][2][4]. They also have an equity stake in a COVID-19 rapid multiplexed test in pre-clinical development through a partnership.
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- Small moleculeNutraceuticalChewing gum formulationEdible productDiagnostic
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Aegea Biotechnologies (COVID-19 assay development)Serendipity BrandsVistaGen Therapeutics
Beyond the preview
Go deeper on Tauriga Sciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tauriga Sciences.